Insider · CIK 0001213029
Otis W Brawley
Files at INCY (INCYTE CORP), A (AGILENT TECHNOLOGIES, INC.), PDSB (PDS Biotechnology Corp), LYEL (Lyell Immunopharma, Inc.). First filing Apr 2, 2025, latest Apr 2, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LYEL: Lyell Immunopharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | LYELbuy Lyell Immunopharma, Inc. | $20k 35,640 shares | - | +11% from low-66% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | INCY INCYTE CORP | AGrant or award Common Stock | +2,518 | $0.00 | $0 | 11,252 | Jun 12, 2025 |
| Jun 10, 2025 | INCY INCYTE CORP | AGrant or award Non Qualfied Stock Option (right to buy)derivative | +9,216 | $0.00 | $0 | 9,216 | Jun 12, 2025 |
| Jun 11, 2025 | PDSB PDS Biotechnology Corp | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,700 | $0.00 | $0 | 22,700 | Jun 11, 2025 |
| May 15, 2025 | LYEL Lyell Immunopharma, Inc. | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| Mar 31, 2025 | LYEL Lyell Immunopharma, Inc. | POpen-market purchase Common Stock | +35,640 | $0.56 | $20k | 35,640 | Apr 2, 2025 |
| Mar 14, 2025 | A AGILENT TECHNOLOGIES, INC. | AGrant or award Common Stock | +1,819 | $121.18 | $220k | 9,930 | Mar 18, 2025 |
| Mar 14, 2025 | A AGILENT TECHNOLOGIES, INC. | AGrant or award Common Stock | +812 | $121.18 | $98k | 10,742 | Mar 18, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.